In summary, we provide evidence that the MEK5/ERK5 pathway promotes activation of the HH/GLI signaling in melanoma cells and that combined targeting of MEK5/ERK5 and HH/GLI signaling pathways might be a promising therapeutic strategy for a subset of melanomas harboring activation of both pathways. The gene discussed is GLI1; the disease is melanoma.